DE122004000025I1 - Borons{ure-und-Esterverbindungen, deren Systhese und Verwendungen. - Google Patents

Borons{ure-und-Esterverbindungen, deren Systhese und Verwendungen.

Info

Publication number
DE122004000025I1
DE122004000025I1 DE200412000025 DE122004000025C DE122004000025I1 DE 122004000025 I1 DE122004000025 I1 DE 122004000025I1 DE 200412000025 DE200412000025 DE 200412000025 DE 122004000025 C DE122004000025 C DE 122004000025C DE 122004000025 I1 DE122004000025 I1 DE 122004000025I1
Authority
DE
Germany
Prior art keywords
boronic acid
ester compounds
synthesis
disclosed
acid compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
DE200412000025
Other languages
English (en)
Inventor
Julian Adams
Yu-Ting Usma
Ross Stein
Matthew Baevsky
Louis Grenier
Louis Plamondon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26987313&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE122004000025(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of DE122004000025I1 publication Critical patent/DE122004000025I1/de
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/26—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having more than one amino group bound to the carbon skeleton, e.g. lysine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic System
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
DE200412000025 1994-10-28 1995-10-27 Borons{ure-und-Esterverbindungen, deren Systhese und Verwendungen. Pending DE122004000025I1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33052594A 1994-10-28 1994-10-28
US08/442,581 US6083903A (en) 1994-10-28 1995-05-16 Boronic ester and acid compounds, synthesis and uses
PCT/US1995/014117 WO1996013266A1 (en) 1994-10-28 1995-10-27 Boronic ester and acid compounds, synthesis and uses

Publications (1)

Publication Number Publication Date
DE122004000025I1 true DE122004000025I1 (de) 2004-09-30

Family

ID=26987313

Family Applications (5)

Application Number Title Priority Date Filing Date
DE69534727T Expired - Lifetime DE69534727T2 (de) 1994-10-28 1995-10-27 Bor Säure- und Ester-Verbindungen, Synthese und Verwendungen
DE69530936T Expired - Lifetime DE69530936T3 (de) 1994-10-28 1995-10-27 Boronsäure-und-esterverbindungen, deren systhese und verwendungen
DE69535866T Expired - Lifetime DE69535866D1 (de) 1994-10-28 1995-10-27 Bor Säure- und Ester-Verbindungen, Synthese und Verwendungen
DE1995630936 Active DE122004000025I2 (de) 1994-10-28 1995-10-27 Borons{ure-und-esterverbindungen, deren Systhese und Verwendungen
DE200412000025 Pending DE122004000025I1 (de) 1994-10-28 1995-10-27 Borons{ure-und-Esterverbindungen, deren Systhese und Verwendungen.

Family Applications Before (4)

Application Number Title Priority Date Filing Date
DE69534727T Expired - Lifetime DE69534727T2 (de) 1994-10-28 1995-10-27 Bor Säure- und Ester-Verbindungen, Synthese und Verwendungen
DE69530936T Expired - Lifetime DE69530936T3 (de) 1994-10-28 1995-10-27 Boronsäure-und-esterverbindungen, deren systhese und verwendungen
DE69535866T Expired - Lifetime DE69535866D1 (de) 1994-10-28 1995-10-27 Bor Säure- und Ester-Verbindungen, Synthese und Verwendungen
DE1995630936 Active DE122004000025I2 (de) 1994-10-28 1995-10-27 Borons{ure-und-esterverbindungen, deren Systhese und Verwendungen

Country Status (25)

Country Link
US (16) US6083903A (de)
EP (4) EP0788360B3 (de)
JP (1) JP3717934B2 (de)
KR (1) KR100398944B1 (de)
CN (2) CN1305475C (de)
AT (3) ATE314378T1 (de)
AU (1) AU710564B2 (de)
CA (2) CA2496538C (de)
CH (1) CH0788360H1 (de)
CY (1) CY2484B1 (de)
DE (5) DE69534727T2 (de)
DK (3) DK1312609T3 (de)
ES (3) ES2314540T3 (de)
FI (2) FI114801B (de)
FR (1) FR04C0014I2 (de)
HK (2) HK1002059A1 (de)
IL (5) IL137726A (de)
LU (1) LU91083I2 (de)
MX (1) MX9703063A (de)
NL (1) NL300151I2 (de)
NO (2) NO310558B1 (de)
NZ (2) NZ296717A (de)
PT (3) PT1312609E (de)
TW (1) TW318850B (de)
WO (1) WO1996013266A1 (de)

Families Citing this family (304)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6838477B2 (en) * 1995-04-12 2005-01-04 President And Fellows Of Harvard College Lactacystin analogs
FR2758329B1 (fr) * 1997-01-16 1999-02-12 Synthelabo Derives d'imidazole-4-butane boronique, leur preparation et leur utilisation en therapeutique
AU741802B2 (en) * 1997-02-15 2001-12-13 Millennium Pharmaceuticals, Inc. Treatment of infarcts through inhibition of NF-kappaB
US6221888B1 (en) * 1997-05-29 2001-04-24 Merck & Co., Inc. Sulfonamides as cell adhesion inhibitors
EP1017398A1 (de) * 1997-09-25 2000-07-12 Proscript, Inc. Proteasome inhibitoren, inhibitoren des ubiquitinweges oder verbindungen, die mit der durch den ubiquitinweg enstehenden nf-kb aktivierung interferieren zur behandlung von entzündlichen und autoimmunerkrankungen
CA2304206A1 (en) * 1997-09-29 1999-04-08 Point Therapeutics, Inc. Stimulation of hematopoietic cells in vitro
US6831057B2 (en) * 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
CA2219867A1 (en) * 1997-10-31 1999-04-30 Jiangping Wu The use of proteasome inhibitors for treating cancer, inflammation, autoimmune disease, graft rejection and septic shock
DE19802450A1 (de) * 1998-01-23 1999-07-29 Hoechst Marion Roussel De Gmbh Ustilipide, Verfahren zu deren Herstellung sowie deren Verwendung
US6075150A (en) 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
US6617171B2 (en) * 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
FR2779653B1 (fr) 1998-06-11 2002-12-20 Inst Nat Sante Rech Med Utilisation de composes modulateurs du proteasome en therapie
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
US6838436B1 (en) * 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6902721B1 (en) * 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6979697B1 (en) * 1998-08-21 2005-12-27 Point Therapeutics, Inc. Regulation of substrate activity
EP0982317A1 (de) * 1998-08-26 2000-03-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalente Proteasome Inhibitore
IL142647A0 (en) * 1998-10-20 2002-03-10 Millenium Pharmaceuticals Inc A method and kit for measuring proteasome activity
US6492333B1 (en) * 1999-04-09 2002-12-10 Osteoscreen, Inc. Treatment of myeloma bone disease with proteasomal and NF-κB activity inhibitors
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
US6649593B1 (en) * 1999-10-13 2003-11-18 Tularik Inc. Modulators of SREBP processing
AU2001287399A1 (en) * 2000-08-16 2002-02-25 University Of Alberta Non-pressurized methods for the preparation of conjugated solid supports for boronic acids
US6919382B2 (en) 2000-08-31 2005-07-19 The Governors Of The University Of Alberta Preparation and uses of conjugated solid supports for boronic acids
EP1430903A1 (de) * 2000-10-12 2004-06-23 Viromics Gmbh Verwendung von Proteasome Hemmern zur Behandlung von Virus-Infektionen
DK1355910T3 (da) * 2001-01-25 2011-06-27 Us Of America Represented By The Secretary Dept Of Health And Human Services Formulering af borsyreforbindelser
CN1509183A (zh) 2001-05-21 2004-06-30 蛋白酶体抑制剂在治疗干眼疾病中的用途
US7112588B2 (en) * 2001-05-21 2006-09-26 Alcon, Inc. Use of proteasome inhibitors to treat dry eye disorders
PT1399468E (pt) * 2001-05-30 2006-05-31 Novartis Ag Derivados do acido 2-{[n-(2-amino-3-(heteroaril ou aril)propionil)-aminoacil]-amino}-alquilboronico
WO2003033507A1 (fr) * 2001-10-12 2003-04-24 Kyorin Pharmaceutical Co., Ltd. Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant
JPWO2003033506A1 (ja) * 2001-10-12 2005-02-03 杏林製薬株式会社 アミノボラン酸誘導体およびそれを含有するプロテアソーム阻害薬
EP1463719A2 (de) * 2002-01-08 2004-10-06 Eisai Co., Ltd Eponemycin und epoxomicin analoge und verwendungen davon
WO2003077928A1 (en) * 2002-03-12 2003-09-25 Ariad Pharmaceuticals, Inc. Peptide analogues and uses thereof
CN100396679C (zh) * 2002-03-13 2008-06-25 詹森药业有限公司 用作组蛋白脱乙酰化酶抑制剂的哌嗪基、哌啶基和吗啉基衍生物
JP4648628B2 (ja) 2002-03-13 2011-03-09 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼの新規な阻害剤としてのカルボニルアミノ誘導体
BR0307599A (pt) 2002-03-13 2005-02-01 Janssen Pharmaceutica Nv Derivados de sulfonilamino como inibidores de histona deacetilase
EA007272B1 (ru) 2002-03-13 2006-08-25 Янссен Фармацевтика Н. В. Новые ингибиторы гистондеацетилазы
US20050203029A1 (en) * 2002-04-05 2005-09-15 Ulrich Schubert Agents for treating <I>flaviviridae</I>infections
US7514579B2 (en) * 2002-06-13 2009-04-07 Johns Hopkins University Boronic chalcone derivatives and uses thereof
WO2004004658A2 (en) * 2002-07-09 2004-01-15 Point Therapeutics, Inc. Methods and compositions relating to isoleucine boroproline compounds
CA2495068A1 (en) * 2002-08-14 2004-02-26 Janssen Pharmaceutica N.V. Use of nf-kappa b inhibitors for the treatment of mastitis
US20050176651A1 (en) * 2002-09-09 2005-08-11 Trigen Limited Peptide boronic acids useful in making salts thereof
US20050282757A1 (en) * 2002-09-09 2005-12-22 Trigen Limited Peptide boronic acid compounds useful in anticoagulation
US20050119226A1 (en) * 2003-09-09 2005-06-02 Trigen Limited Methods for synthesizing organoboronic compounds and products thereof
US20050288253A1 (en) * 2002-09-09 2005-12-29 Trigen Limited Boronic acid salts
US20060084592A1 (en) * 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
EP1561466A3 (de) * 2002-09-09 2006-08-23 Trigen Limited Borsäuresalze und deren Verwendung in der Bereitstellung von Medikamente für die Thrombosebehandlung
CN1684738A (zh) * 2002-09-20 2005-10-19 爱尔康公司 细胞因子合成抑制剂用于治疗干眼病的用途
ES2542328T3 (es) 2002-12-06 2015-08-04 Millennium Pharmaceuticals, Inc. Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma
CN100341880C (zh) * 2003-02-13 2007-10-10 上海仁虎制药股份有限公司 新型硼酸或硼酸酯类化合物、制备方法及在药学上的应用
US20070110785A1 (en) * 2003-07-03 2007-05-17 Eugene Tedeschi Medical devices with proteasome inhibitors for the treatment of restenosis
US7576206B2 (en) * 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7223745B2 (en) * 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
SG148161A1 (en) 2003-11-05 2008-12-31 Palingen Inc Enhanced b cell cytotoxicity of cdim binding antibody
US20060052390A1 (en) * 2003-12-24 2006-03-09 Scios, Inc. Treatment of multiple myeloma by p38 MAP kinase and proteasome inhibition
CA2558106A1 (en) * 2004-02-23 2005-09-09 Trustees Of Tufts College Inhibitors of dipeptidylpeptidase iv for regulating glucose metabolism
GB0405272D0 (en) * 2004-03-09 2004-04-21 Trigen Ltd Compounds
US7371875B2 (en) * 2004-03-12 2008-05-13 Miikana Therapeutics, Inc. Cytotoxic agents and methods of use
DK2377869T3 (da) * 2004-03-30 2014-04-14 Millennium Pharm Inc Syntese af Bortezomib
AU2016202747B2 (en) * 2004-03-30 2017-11-23 Millennium Pharmaceuticals, Inc. Synthesis of boronic ester and acid compounds
US8198270B2 (en) 2004-04-15 2012-06-12 Onyx Therapeutics, Inc. Compounds for proteasome enzyme inhibition
CN103554222A (zh) 2004-04-15 2014-02-05 欧尼斯治疗公司 用于抑制蛋白酶体酶的化合物
CN102875642A (zh) 2004-05-10 2013-01-16 普罗特奥里克斯公司 用于酶抑制的化合物
WO2006002422A2 (en) 2004-06-24 2006-01-05 Novartis Vaccines And Diagnostics Inc. Compounds for immunopotentiation
EP1794120B1 (de) 2004-07-23 2012-04-11 Nuada, LLC Peptidaseinhibitoren
AU2005266312C1 (en) * 2004-07-28 2011-06-16 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
CA2584515A1 (en) 2004-10-20 2006-04-27 Proteolix, Inc. Labeled compounds for proteasome inhibition
EP1814913B1 (de) 2004-11-05 2015-08-19 IGM Biosciences, Inc. Antikörperinduzierte zellmembranverletzung
TW200618820A (en) * 2004-11-05 2006-06-16 Alza Corp Liposome formulations of boronic acid compounds
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
US20070098685A1 (en) * 2005-01-19 2007-05-03 Brand Stephen J Methods and kits to treat chronic inflammatory immune diseases by administering a proteasome inhibitor and an interleukin 2 receptor agonist
AU2006207325B2 (en) 2005-01-21 2012-08-16 Astex Therapeutics Limited Pharmaceutical compounds
CA2595749A1 (en) * 2005-01-27 2006-08-03 Research Development Foundation Combination therapy with triterpenoid compounds and proteasome inhibitors
US7468383B2 (en) * 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
JP5038912B2 (ja) 2005-02-16 2012-10-03 アナコール ファーマシューティカルズ，インコーポレイテッド ホウ素含有小分子
US7589066B2 (en) * 2005-03-11 2009-09-15 The University Of North Carolina At Chapel Hill Potent and specific immunoproteasome inhibitors
AU2006242446A1 (en) * 2005-04-29 2006-11-09 Kosan Biosciences Incorporated Method of treating multiple myeloma using 17-AAG or 17-AG or a prodrug of either in combination with a proteasome inhibitor
DK1885710T3 (en) 2005-05-18 2015-11-23 Janssen Pharmaceutica Nv SUBSTITUTED AMINOPROPENYLPIPERIDINE OR MORPHOLINE DERIVATIVES AS UNKNOWN INHIBITORS OF HISTONDEACETYLASE
AU2006202209B2 (en) * 2005-05-27 2011-04-14 Lifescan, Inc. Amniotic fluid derived cells
CN101484575B (zh) * 2005-06-08 2013-10-02 森托科尔公司 用于眼变性的细胞疗法
EP1912664A2 (de) * 2005-07-06 2008-04-23 Biodevelops Pharma Entwicklung GmbH Verwendung einer verbindung zur verstärkung der expression von membranproteinen auf der zelloberfläche
EP1752467A1 (de) 2005-08-10 2007-02-14 4Sc Ag Krebszellen-, t-Zellen- und Keratinocyte-Proliferation-Inhibitoren
US7531517B2 (en) 2005-08-10 2009-05-12 4Sc Ag Inhibitors of cancer cell, T-cell and keratinocyte proliferation
US20070059382A1 (en) * 2005-09-09 2007-03-15 Board Of Regents, Univ. And Comm. College System Of Nevada... Medical treatment of breast cancer with boric acid materials
DK2623113T3 (en) 2005-11-09 2017-07-17 Onyx Therapeutics Inc Enzyme inhibition compound
WO2007067752A2 (en) * 2005-12-08 2007-06-14 Cytokinetics, Inc. Certain compositions and methods of treatment
CN106008583A (zh) 2005-12-30 2016-10-12 安纳考尔医药公司 含硼的小分子
EP1979326B1 (de) 2006-01-19 2012-10-03 Janssen Pharmaceutica N.V. Pyridin- und pyrimidinderivate als inhibitoren von histondeacetylase
US8101616B2 (en) * 2006-01-19 2012-01-24 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
PL1981874T3 (pl) * 2006-01-19 2009-10-30 Janssen Pharmaceutica Nv Pochodne aminofenylowe jako nowe inhibitory deacetylazy histonowej
AU2007206950B2 (en) * 2006-01-19 2012-02-02 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
PT2719388T (pt) 2006-02-16 2019-06-11 Anacor Pharmaceuticals Inc Moléculas pequenas que contêm boro como agentes antiinflamatórios
AR060358A1 (es) * 2006-04-06 2008-06-11 Novartis Vaccines & Diagnostic Quinazolinas para la inhibicion de pdk 1
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
DE102006026464A1 (de) 2006-06-01 2007-12-06 Virologik Gmbh Innovationszentrum Medizintechnik Und Pharma Pharmazeutische Zusammensetzung zur Behandlung von Virusinfektionen und / oder Tumorerkrankungen durch Inhibition der Proteinfaltung und des Proteinabbaus
WO2007143600A2 (en) * 2006-06-05 2007-12-13 Incyte Corporation Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
PT2041158E (pt) 2006-06-19 2013-07-17 Onyx Therapeutics Inc Péptido epoxicetonas para inibição de proteassoma
WO2008031817A2 (en) * 2006-09-15 2008-03-20 Janssen Pharmaceutica Nv Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors
EP2066328A2 (de) * 2006-09-15 2009-06-10 Janssen Pharmaceutica N.V. Kombinationen aus klasse-1-spezifischen histon-deacetylasehemmern mit proteasomhemmern
US8883790B2 (en) 2006-10-12 2014-11-11 Astex Therapeutics Limited Pharmaceutical combinations
US8916552B2 (en) 2006-10-12 2014-12-23 Astex Therapeutics Limited Pharmaceutical combinations
CA2606634A1 (en) * 2006-12-08 2008-06-08 Centenary Institute Of Cancer Medicine And Cell Biology Assay for response to proteasome inhibitors
JO3396B1 (ar) 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
DK2185693T3 (da) 2007-07-31 2019-09-23 Lifescan Inc Differentiering af humane embryoniske stamceller
CA2685540C (en) 2007-08-03 2018-10-16 Graham Michael Wynne Drug combinations for the treatment of duchenne muscular dystrophy
GB0715087D0 (en) 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
UA97536C2 (en) * 2007-08-06 2012-02-27 Милленниум Фармасьютикалз, Инк. Proteasome inhibitors
US7442830B1 (en) 2007-08-06 2008-10-28 Millenium Pharmaceuticals, Inc. Proteasome inhibitors
EA034601B1 (ru) * 2007-08-06 2020-02-25 Милленниум Фармасьютикалз, Инк. Способ получения бороновых кислот
AU2016253697A1 (en) * 2007-08-06 2016-11-24 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
AU2008298694A1 (en) * 2007-09-12 2009-03-19 Dr. Reddy's Laboratories Ltd. Bortezomib and process for producing same
US20090076031A1 (en) * 2007-09-17 2009-03-19 Protia, Llc Deuterium-enriched bortezomib
AU2008307510A1 (en) 2007-10-04 2009-04-09 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
US7838673B2 (en) * 2007-10-16 2010-11-23 Millennium Pharmaceuticals, Inc. Proteasome inhibitors
US20090110688A1 (en) * 2007-10-24 2009-04-30 Georg Fertig Combination therapy of type ii anti-cd20 antibody with a proteasome inhibitor
JP5710264B2 (ja) * 2007-11-27 2015-04-30 ライフスキャン・インコーポレイテッドＬｉｆｅｓｃａｎ，Ｉｎｃ． ヒト胚性幹細胞の分化
CN101220048B (zh) * 2007-12-14 2012-08-15 江苏先声药物研究有限公司 ZnCl2催化下的蒎烷二醇酯的制备方法
US8940771B2 (en) 2007-12-20 2015-01-27 Novartis Ag Organic compounds
AU2009215516B2 (en) 2008-02-21 2014-12-18 Janssen Biotech Inc. Methods, surface modified plates and compositions for cell attachment, cultivation and detachment
KR101672511B1 (ko) 2008-03-06 2016-11-03 아나코르 파마슈티칼스 인코포레이티드 소염제로써 붕소가 함유된 소분자
EP2285384A4 (de) * 2008-05-12 2012-04-25 Anacor Pharmaceuticals Inc Borhaltige kleine moleküle
RS54020B1 (en) 2008-06-17 2015-10-30 Millennium Pharmaceuticals Inc. ORGANOBOR ESTAR UNITS AND THEIR PHARMACEUTICAL COMPOSITIONS
AU2009267137A1 (en) 2008-06-30 2010-01-07 Centocor Ortho Biotech Inc. Differentiation of pluripotent stem cells
CN101638414B (zh) * 2008-07-30 2014-01-08 江苏先声药物研究有限公司 肽硼酸及其酯类化合物、制备方法及其用途
US20100028307A1 (en) * 2008-07-31 2010-02-04 O'neil John J Pluripotent stem cell differentiation
US8461336B2 (en) 2008-09-04 2013-06-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
WO2010027975A1 (en) * 2008-09-04 2010-03-11 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
AR075090A1 (es) * 2008-09-29 2011-03-09 Millennium Pharm Inc Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden.
US9493489B2 (en) * 2008-10-15 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
KR20110073584A (ko) 2008-10-21 2011-06-29 오닉스 세라퓨틱스, 인크. 펩티드 에폭시케톤과의 병용 요법
RU2528861C2 (ru) * 2008-10-31 2014-09-20 Сентокор Орто Байотек Инк. Дифференцирование человеческих эмбриональных стволовых клеток в линию панкреатических эндокринных клеток
CA2742268C (en) 2008-10-31 2020-02-18 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
PL2366022T3 (pl) * 2008-11-20 2016-11-30 Sposoby i kompozycje do przyłączania i hodowli komórek na podłożach planarnych
ES2642070T3 (es) 2008-11-20 2017-11-15 Janssen Biotech, Inc. Cultivo de células madre pluripotentes en microportadores
CN101747354B (zh) * 2008-12-04 2014-08-13 江苏先声药物研究有限公司 一类β氨基酸组成的二肽硼酸及其酯类化合物、制备方法及其用途
AU2009335744A1 (en) * 2008-12-17 2010-07-15 Anacor Pharmaceuticals, Inc. Polymorphs of (S)-3-aminomethyl-7-(3-hydroxy-propoxy) -3H-benzo[c][1,2] oxaborol-1-ol
JP5689816B2 (ja) 2009-01-09 2015-03-25 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド 非経口用医薬組成物及びその非経口用医薬組成物の製造方法
EP3021120A1 (de) 2009-02-20 2016-05-18 Michael P. Lisanti Verfahren zur diagnose oder prognose eines neoplasmas einschliesslich der bestimmung des expressionsgrads eines proteins in stromazellen neben dem neoplasma
JP5709766B2 (ja) 2009-03-12 2015-04-30 ジェネンテック， インコーポレイテッド 造血器腫瘍の治療のためのホスホイノシチド３キナーゼ阻害剤化合物と化学療法剤の併用
WO2010106135A1 (en) 2009-03-20 2010-09-23 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Combined use for the treatment of ovarian carcinoma
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
CA2756193A1 (en) 2009-03-24 2010-09-30 Janssen Pharmaceutica Nv Biomarkers for assessing peripheral neuropathy response to treatment with a proteasome inhibitor
CA2756072A1 (en) * 2009-03-30 2010-10-14 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
WO2010114770A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
WO2010114768A1 (en) * 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-epothilone conjugates, particles, compositions, and related methods of use
MX2011012538A (es) * 2009-05-27 2012-02-08 Cephalon Inc Terapia de combinacion para el tratamiento del mieloma multiple.
EP2280016A1 (de) 2009-07-27 2011-02-02 LEK Pharmaceuticals d.d. Neue synthetische Route zur Herstellung von Alpha-Aminoborestern über substituierte Alylene
EP2270019A1 (de) 2009-06-19 2011-01-05 LEK Pharmaceuticals d.d. Neue synthetische Route zur Herstellung von alpha-Aminoborestern
EP2443128B1 (de) 2009-06-19 2017-12-20 LEK Pharmaceuticals d.d. Neue synthetische Route zur Herstellung von alpha-Aminoboronsäure-estern
CN101928329B (zh) * 2009-06-19 2013-07-17 北京大学 三肽硼酸(酯)类化合物、其制备方法和应用
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
DE102009027754A1 (de) 2009-07-15 2011-05-05 Schubert, Ulrich, Dr. Verfahren zur Hemmung der Reifung von dendritischen Zellen
JP6219568B2 (ja) 2009-07-20 2017-10-25 ヤンセン バイオテツク，インコーポレーテツド ヒト胚性幹細胞の分化
ES2693088T3 (es) * 2009-07-20 2018-12-07 Janssen Biotech, Inc. Diferenciación de células madre embriónicas humanas
AR077766A1 (es) 2009-07-20 2011-09-21 Janssen Biotech Inc Diferenciacion de celulas madre embrionarias humanas
BR112012001987A2 (pt) * 2009-07-28 2015-09-01 Anacor Pharmaceuticals Inc Composto, combinação, formulação farmacêutica, uso de um composto, uma combinação ou um sal farmaceuticamente aceitável dos mesmos, e, métodos para tratar uma infecção bacteriana, para matar ou inibir o crescimento de uma bactéria, e para inibir uma beta-lactamase.
AP4039A (en) * 2009-08-14 2017-02-28 Daitao Chen Boron-containing small molecules as antiprotozoal agents
US20120149663A1 (en) 2009-08-18 2012-06-14 Georgetown University Boronic acid compositions and methods related to cancer
US20110207701A1 (en) * 2009-08-19 2011-08-25 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
CA2770252C (en) 2009-09-08 2018-06-12 F. Hoffmann-La Roche Ag 4-substituted pyridin-3-yl-carboxamide compounds and uses thereof for treating cancer
WO2011037731A1 (en) * 2009-09-25 2011-03-31 Anacor Pharmaceuticals, Inc. Boron containing small molecules
EP2305285A1 (de) 2009-09-29 2011-04-06 Julius-Maximilians-Universität Würzburg Mittel und Verfahren zur Behandlung von ischämischen Erkrankungen
EP2519231B1 (de) 2009-10-01 2017-03-15 Janssen Pharmaceutica NV Behandlung von erkrankungen mit proteasomhemmern
WO2011049971A1 (en) 2009-10-20 2011-04-28 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as antiprotozoal agents
WO2011060199A1 (en) * 2009-11-11 2011-05-19 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
JP5919196B2 (ja) 2009-11-13 2016-05-18 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 転移抑制のためのペプチドエポキシケトンの使用
MX2012007341A (es) 2009-12-22 2012-07-20 Cephalon Inc Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
CN102741395B (zh) 2009-12-23 2016-03-16 詹森生物科技公司 人胚胎干细胞的分化
CN102712902B (zh) 2009-12-23 2019-01-08 詹森生物科技公司 人胚胎干细胞的分化
US20110178287A1 (en) 2010-01-19 2011-07-21 Cerulean Pharma Inc. Cyclodextrin-based polymers for therapeutic delivery
WO2011094450A1 (en) 2010-01-27 2011-08-04 Anacor Pharmaceuticals, Inc Boron-containing small molecules
MX2012010017A (es) * 2010-03-01 2012-10-01 Onyx Therapeutics Inc Compuestos de para la inhibicion de inmunoproteasomas.
WO2011109279A2 (en) * 2010-03-01 2011-09-09 Centocor Ortho Biotech Inc. Methods for purifying cells derived from pluripotent stem cells
US8263578B2 (en) 2010-03-18 2012-09-11 Innopharma, Inc. Stable bortezomib formulations
US9061037B2 (en) * 2010-03-18 2015-06-23 Innopharma, Inc. Stable bortezomib formulations
AP2012006482A0 (en) 2010-03-19 2012-10-31 Anacor Pharmacueticals Inc Boron-containing small molecules as anti-protozoalagent
EP2550362B1 (de) 2010-03-25 2017-01-04 Oregon Health&Science University Cmv-glycoproteine und rekombinante vektoren
KR20130036228A (ko) * 2010-03-31 2013-04-11 밀레니엄 파머슈티컬스 인코퍼레이티드 1-아미노-2-사이클로프로필에틸보론산의 유도체
AU2013204868B2 (en) * 2010-03-31 2016-10-13 Millennium Pharmaceuticals, Inc. Derivatives of 1-amino-2-cyclopropylethylboronic acid
US8697646B2 (en) 2010-04-07 2014-04-15 Onyx Therapeutics, Inc. Crystalline peptide epoxyketone immunoproteasome inhibitor
CN101812026B (zh) * 2010-04-12 2013-08-28 亚邦医药股份有限公司 一种硼替佐米的合成方法
CN102946879B (zh) 2010-04-19 2015-04-22 尼基制药公司 一种蛋白酶体抑制剂和镓络合物在制备治疗增殖性疾病的药物中的应用
US8809282B2 (en) 2010-05-06 2014-08-19 Duke University Method of reducing titers of antibodies specific for a therapeutic agent
SG10201503652WA (en) 2010-05-12 2015-08-28 Janssen Biotech Inc Differentiation of human embryonic stem cells
CA2799202C (en) 2010-05-18 2016-07-05 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
EP3372672A1 (de) 2010-08-31 2018-09-12 Janssen Biotech, Inc. Differenzierung menschlicher embryonischer stammzellen
CN108517310B (zh) 2010-08-31 2022-02-15 詹森生物科技公司 人胚胎干细胞的分化
SG187947A1 (en) 2010-08-31 2013-03-28 Janssen Biotech Inc Differentiation of pluripotent stem cells
US9126997B1 (en) 2010-09-07 2015-09-08 Northwestern University Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma
HRP20211762T1 (hr) 2010-09-07 2022-02-18 Anacor Pharmaceuticals, Inc. Derivati benzoksaborola za liječenje bakterijskih infekcija
EP2624818B1 (de) 2010-10-05 2017-04-05 Fresenius Kabi USA, LLC Mit borsäure stabilisierte bortezomib-formulierungen
US8884009B2 (en) 2010-10-14 2014-11-11 Synthon Bv Process for making bortezomib and intermediates for the process
AU2012213080B2 (en) 2011-01-31 2014-03-27 Novartis Ag Novel heterocyclic derivatives
TW201309303A (zh) * 2011-03-03 2013-03-01 Cephalon Inc 用於治療狼瘡的蛋白酶體抑制劑
WO2012135528A2 (en) 2011-03-29 2012-10-04 Texas Tech University System Galectin-3c combination therapy for human cancer
WO2012133884A1 (ja) 2011-03-31 2012-10-04 ナノキャリア株式会社 ボロン酸化合物を含有したブロック共重合体を含む医薬組成物
CA2832109C (en) 2011-06-10 2021-07-06 Oregon Health & Science University Cmv glycoproteins and recombinant vectors
MX2013015308A (es) * 2011-06-22 2014-05-20 Cephalon Inc Inhibidores de proteasoma y procesos para su preparacion, purificacion y uso.
US8481655B2 (en) 2011-07-27 2013-07-09 Wacker Chemical Corporation Copper complexes of amino-functional organosilicon compounds and their use
RS55053B1 (sr) 2011-08-11 2016-12-30 Janssen Pharmaceutica Nv Prediktori za lečenje kancera
WO2013021032A1 (en) 2011-08-11 2013-02-14 Janssen Pharmaceutica Nv Histone deacetylase inhibitors in combination with proteasome inhibitors and dexamethasone
SG10201606883QA (en) 2011-08-19 2016-10-28 Glaxo Group Ltd Benzofuran compounds for the treatment of hepatitis c virus infections
ES2929179T3 (es) * 2011-08-30 2022-11-25 Tufts College Inhibidores del proteasoma activados por FAP para el tratamiento de tumores sólidos
AU2012216792A1 (en) 2011-09-12 2013-03-28 International Aids Vaccine Initiative Immunoselection of recombinant vesicular stomatitis virus expressing HIV-1 proteins by broadly neutralizing antibodies
US9402894B2 (en) 2011-10-27 2016-08-02 International Aids Vaccine Initiative Viral particles derived from an enveloped virus
ES2776144T3 (es) 2011-10-28 2020-07-29 Millennium Pharm Inc Biomarcadores de respuesta a inhibidores de NAE
CN104039790B (zh) 2011-10-28 2016-04-13 诺华股份有限公司 嘌呤衍生物及它们在治疗疾病中的应用
JP6286358B2 (ja) 2011-11-11 2018-02-28 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤に応答するバイオマーカー
EP2776043B1 (de) 2011-11-11 2018-02-21 Millennium Pharmaceuticals, Inc. Biomarker der reaktion auf proteasomenhemmer
JP5481614B2 (ja) 2011-11-17 2014-04-23 国立大学法人 東京大学 フェニルボロン酸基が導入されたブロックコポリマーおよびその使用
AU2012355698B2 (en) 2011-12-22 2018-11-29 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into single hormonal insulin positive cells
US9732101B2 (en) 2012-01-18 2017-08-15 Wisconsin Alumni Research Foundation Bioreversible boronates for delivery of molecules into cells
US9234048B2 (en) 2012-01-18 2016-01-12 Wisconsin Alumni Research Foundation Boronate-mediated delivery of molecules into cells
CA2862492A1 (en) 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
GB2523211B (en) 2012-01-27 2020-03-18 Univ Jefferson MCT protein inhibitor-related prognostic and therapeutic methods
MX363819B (es) 2012-02-08 2019-04-03 Igm Biosciences Inc Uniones a cdim y sus usos.
CA2866135A1 (en) 2012-03-02 2014-09-06 Dr. Reddy's Laboratories Limited Pharmaceutical compositions comprising boronic acid compounds
RU2018128383A (ru) 2012-03-07 2019-03-14 Янссен Байотек, Инк. Среда определенного состава для размножения и обновления плюрипотентных стволовых клеток
CA2784240C (en) 2012-03-27 2014-07-08 Innopharma, Inc. Stable bortezomib formulations
SG11201406550QA (en) 2012-05-16 2014-11-27 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
EP3450543A1 (de) 2012-06-08 2019-03-06 Janssen Biotech, Inc. Differenzierung humaner embryonaler stammzellen in endokrine pankreaszellen
ES2631608T3 (es) 2012-06-27 2017-09-01 International Aids Vaccine Initiative Variante de la glicoproteína Env del VIH-1
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
JP2013006855A (ja) * 2012-09-03 2013-01-10 Millennium Pharmaceuticals Inc プロテアソーム阻害剤
JP2015532915A (ja) * 2012-09-11 2015-11-16 シプラ・リミテッド ボルテゾミブの製造方法
JP6486826B2 (ja) 2012-10-01 2019-03-20 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 阻害剤に対する応答を予測するためのバイオマーカーおよび方法、ならびにそれらの使用
WO2014072985A1 (en) 2012-11-06 2014-05-15 Natco Pharma Limited Novel boronic acid derivatives as anti cancer agents
NZ630287A (en) 2012-11-16 2016-07-29 Shilpa Medicare Ltd Crystalline bortezomib process
WO2014097306A1 (en) 2012-12-21 2014-06-26 Natco Pharma Limited Stable and pure polymorphic form of bortezomib
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
RU2658488C2 (ru) 2012-12-31 2018-06-21 Янссен Байотек, Инк. Способ получения клеток, экспрессирующих маркеры, характерные для панкреатических эндокринных клеток
ES2906998T3 (es) 2012-12-31 2022-04-21 Janssen Biotech Inc Suspensión y agrupación de células pluripotentes humanas para su diferenciación en células endocrinas pancreáticas
CA2896658C (en) 2012-12-31 2021-06-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells using hb9 regulators
CN112521369A (zh) 2013-03-13 2021-03-19 福马治疗股份有限公司 用于抑制fasn的化合物及组合物
EP2986619A1 (de) 2013-04-16 2016-02-24 Cipla Limited Verfahren zur herstellung von bortezomib-mannitol-ester
US10022372B2 (en) 2013-04-19 2018-07-17 Thomas Jefferson University Caveolin-1 related methods for treating glioblastoma with temozolomide
US9603775B2 (en) 2013-04-24 2017-03-28 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
WO2015003146A1 (en) 2013-07-03 2015-01-08 Georgetown University Boronic acid derivatives of resveratrol for activating deacetylase enzymes
US20150065381A1 (en) 2013-09-05 2015-03-05 International Aids Vaccine Initiative Methods of identifying novel hiv-1 immunogens
EP3052105A1 (de) 2013-10-03 2016-08-10 Millennium Pharmaceuticals, Inc. Verfahren zur prophylaxe oder behandlung von systemischem lupus erythematosus und/oder lupus nephritis
US10058604B2 (en) 2013-10-07 2018-08-28 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
CN104586776B (zh) * 2013-10-30 2017-05-17 扬子江药业集团上海海尼药业有限公司 以硼替佐米为活性成分的制剂及其制备方法
JP6468562B2 (ja) * 2013-11-21 2019-02-13 国立大学法人北海道大学 プロテアソーム阻害性化合物
US10191033B2 (en) 2013-12-05 2019-01-29 The Broad Institute, Inc. Biomarkers for detecting pre-cachexia or cachexia and methods of treatment thereof
DK3076969T3 (da) 2013-12-06 2021-11-22 Novartis Ag Doseringsregime for en alfa-isoform-selektiv phosphatidylinositol-3-kinase-hæmmer
CN106132970B (zh) 2014-02-03 2020-09-04 俄亥俄州创新基金会 硼酸酯和其药物制剂
EP2910557A1 (de) * 2014-02-20 2015-08-26 Ikerchem, S.L. Enantiomerenreine tetrasubstituierte Pyrrolidine als Gerüste für Proteasomhemmer und medizinische Anwendungen davon
JP6566936B2 (ja) 2014-05-08 2019-08-28 国立大学法人 東京大学 医薬組成物
WO2015175307A1 (en) 2014-05-16 2015-11-19 Janssen Biotech, Inc. Use of small molecules to enhance mafa expression in pancreatic endocrine cells
UA121389C2 (uk) 2014-05-20 2020-05-25 Мілленніум Фармасьютікалз, Інк. Борвмісні інгібітори протеасом для застосування після первинної протиракової терапії
EP4180041A1 (de) 2014-08-07 2023-05-17 Mayo Foundation for Medical Education and Research Verbindungen und verfahren zur behandlung von krebs
BR112017006349A2 (pt) * 2014-10-01 2017-12-12 Merck Patent Gmbh derivados de ácido borônico
WO2016110870A1 (en) 2015-01-07 2016-07-14 Emcure Pharmaceuticals Limited Pharmaceutical composition of bortezomid
MA41505A (fr) 2015-02-11 2017-12-19 Millennium Pharm Inc Nouvelle forme cristalline d'un inhibiteur de protéasome
EP3270891A1 (de) 2015-03-17 2018-01-24 Leon-Nanodrugs GmbH Nanopartikel mit einer stabilisierten boronsäureverbindung
US10174292B2 (en) 2015-03-20 2019-01-08 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
US9931394B2 (en) 2015-03-23 2018-04-03 International Aids Vaccine Initiative Soluble HIV-1 envelope glycoprotein trimers
WO2016184793A1 (en) 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
WO2016205790A2 (en) 2015-06-19 2016-12-22 Hanlin Scientific, Inc. Chiral specific boron-containing compounds and their use in treating cancer or amyloidosis
EP3120837A1 (de) 2015-07-22 2017-01-25 Stada Arzneimittel Ag Verfahren zur herstellung einer bortezomibester-lösung
CN106478700B (zh) * 2015-08-26 2020-12-29 杭州雷索药业有限公司 硼基取代的苯胺类蛋白激酶抑制剂
CN106588965A (zh) * 2015-10-15 2017-04-26 北京大学 脲拟肽硼酸化合物及其药物组合物、制备方法和用途
CA3002954A1 (en) 2015-11-02 2017-05-11 Novartis Ag Dosage regimen for a phosphatidylinositol 3-kinase inhibitor
EP3389715A4 (de) 2015-12-14 2019-06-12 David K. Thomas Zusammensetzungen und verfahren zur behandlung von kardialer dysfunktion
CN107151255A (zh) * 2016-03-06 2017-09-12 复旦大学 硼酸类化合物及其制备方法和用途
CN107151254A (zh) * 2016-03-06 2017-09-12 复旦大学 一种作为20s蛋白酶体抑制剂的硼酸类化合物及其制备方法
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
US11447506B2 (en) 2016-05-09 2022-09-20 Anacor Pharmaceuticals, Inc. Crystal forms of crisaborole in free form and preparation method and use thereof
CN106008572B (zh) * 2016-05-23 2018-08-17 成都千禧莱医药科技有限公司 一类二肽硼酸化合物及制备方法和用途
PT3472149T (pt) 2016-06-21 2023-11-23 Orion Opthalmology Llc Derivados de prolinamida heterocíclicos
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
JP6681284B2 (ja) * 2016-06-23 2020-04-15 信越化学工業株式会社 糖アルコール化合物の金属低減方法
JP6223508B2 (ja) * 2016-06-27 2017-11-01 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
WO2018038687A1 (en) 2016-08-22 2018-03-01 Mustafa Nevzat Ilaç Sanayii A.Ş. Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
CA3040820A1 (en) 2016-10-20 2018-04-26 Pfizer Inc. Therapeutic particles with peptide boronic acid or boronate ester compounds and methods of making and using same
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CA3049435A1 (en) 2017-01-09 2018-07-12 Scott Grindrod Selective histone deacetylase inhibitors for the treatment of human disease
EP3583110A1 (de) 2017-02-17 2019-12-25 Fresenius Kabi Oncology Ltd Verbessertes verfahren zur herstellung von boronsäureestern
EP3589659A4 (de) 2017-02-28 2021-03-24 Mayo Foundation for Medical Education and Research Verbindungen und verwendung zur behandlung von krebs
US20210128667A1 (en) 2017-08-23 2021-05-06 Kezar Life Sciences Immunoproteasome inhibitors and immunosuppressive agent in the treatment of autoimmune disorders
BR112020005079A2 (pt) 2017-09-14 2020-09-15 Glaxosmithkline Intellectual Property Development Limited tratamento de combinação para câncer
JP2018024694A (ja) * 2017-10-03 2018-02-15 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． プロテアソーム阻害剤
SG11202003867SA (en) 2017-11-16 2020-05-28 Principia Biopharma Inc Immunoproteasome inhibitors
MX2020005036A (es) * 2017-11-16 2020-08-17 Principia Biopharma Inc Inhibidores de inmunoproteasoma.
US10537585B2 (en) 2017-12-18 2020-01-21 Dexcel Pharma Technologies Ltd. Compositions comprising dexamethasone
US11407723B2 (en) 2018-01-09 2022-08-09 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
US20210106522A1 (en) 2018-01-29 2021-04-15 Cognos Therapeutics, Inc. Intratumoral delivery of bortezomib
TW202003553A (zh) 2018-03-15 2020-01-16 美商艾伯維有限公司 用於治療癌症之abbv-621與抗癌劑之組合
US11243207B2 (en) 2018-03-29 2022-02-08 Mayo Foundation For Medical Education And Research Assessing and treating cancer
US10793554B2 (en) 2018-10-29 2020-10-06 Forma Therapeutics, Inc. Solid forms of 4-(2-fluoro-4-(1-methyl-1H-benzo[d]imidazol-5-yl)benzoyl)piperazin-1-yl)(1-hydroxycyclopropyl)methanone
CN109824756B (zh) * 2019-03-19 2022-03-22 山东大学 含有4-(苯磺酰基)哌嗪-2-酮的苯丙氨酸衍生物及其制备方法与应用
CN114437119A (zh) * 2020-10-30 2022-05-06 苏州开拓药业股份有限公司 一种c-Myc蛋白抑制剂及其制备方法和用途
WO2022120039A2 (en) * 2020-12-02 2022-06-09 Steven Hoffman Compositions and methods for modulating cancer in non-human mammals
TW202237143A (zh) * 2020-12-10 2022-10-01 南韓商Ｌｇ化學股份有限公司 酸（Ｂｏｒｏｎｉｃ Ａｃｉｄ）化合物
US11964993B2 (en) 2021-07-03 2024-04-23 Shilpa Pharma Lifesciences Limited Crystalline bortezomib process
US20230062279A1 (en) 2021-08-12 2023-03-02 Extrovis Ag Pharmaceutical compositions of bortezomib
CN113957441B (zh) * 2021-10-29 2024-01-02 光华科学技术研究院(广东)有限公司 蚀刻液及其制备方法和应用
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261868A (en) * 1979-08-08 1981-04-14 Lever Brothers Company Stabilized enzymatic liquid detergent composition containing a polyalkanolamine and a boron compound
US4369183A (en) * 1979-09-06 1983-01-18 Merck & Co., Inc. 2-Pyridyl-1,2-benzisothiazolinone-1,1-dioxides and their use as selective protease inhibitors
US4510130A (en) 1983-05-20 1985-04-09 Genetic Diagnostics Corporation Promoting animal and plant growth with leupeptin
US4537773A (en) 1983-12-05 1985-08-27 E. I. Du Pont De Nemours And Company α-Aminoboronic acid derivatives
US4499082A (en) * 1983-12-05 1985-02-12 E. I. Du Pont De Nemours And Company α-Aminoboronic acid peptides
US4537707A (en) * 1984-05-14 1985-08-27 The Procter & Gamble Company Liquid detergents containing boric acid and formate to stabilize enzymes
US4842769A (en) * 1985-07-26 1989-06-27 Colgate-Palmolive Co. Stabilized fabric softening built detergent composition containing enzymes
US4759032A (en) 1987-06-03 1988-07-19 Monsanto Company Electrode seal assembly
US5242904A (en) * 1987-06-05 1993-09-07 The Dupont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
US5250720A (en) * 1987-06-05 1993-10-05 The Dupont Merck Pharmaceutical Company Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) * 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
SE8702550D0 (sv) * 1987-06-18 1987-06-18 Anders Grubb Cysteinproteashemmare
EP0374157B1 (de) 1987-06-19 1994-07-06 The Regents Of The University Of California Neue klasse von niedrigkalorischen proteinsüssstoffen
EP0315574A3 (de) * 1987-11-05 1990-08-22 Hoechst Aktiengesellschaft Renin-Inhibitoren
US4963655A (en) * 1988-05-27 1990-10-16 Mayo Foundation For Medical Education And Research Boron analogs of amino acid/peptide protease inhibitors
US5106948A (en) * 1988-05-27 1992-04-21 Mao Foundation For Medical Education And Research Cytotoxic boronic acid peptide analogs
DE3827340A1 (de) * 1988-08-12 1990-02-15 Hoechst Ag Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen
ZA897515B (en) * 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
US4997929A (en) * 1989-01-05 1991-03-05 Synergen, Inc. Purified ciliary neurotrophic factor
US4959179A (en) * 1989-01-30 1990-09-25 Lever Brothers Company Stabilized enzymes liquid detergent composition containing lipase and protease
JP2701932B2 (ja) * 1989-04-10 1998-01-21 サントリー株式会社 タンパク質分解酵素阻害剤
US5030378A (en) * 1990-01-02 1991-07-09 The Procter & Gamble Company Liquid detergents containing anionic surfactant, builder and proteolytic enzyme
JPH05506777A (ja) 1990-03-05 1993-10-07 セファロン、インコーポレーテッド キモトリプシン様プロテアーゼ及びそれらの阻害剤
GB9017694D0 (en) * 1990-08-13 1990-09-26 Sandoz Ltd Improvements in or relating to organic chemistry
EP0478050A1 (de) * 1990-09-24 1992-04-01 Unilever N.V. Detergentzusammensetzung
GB9024129D0 (en) * 1990-11-06 1990-12-19 Thrombosis Research Trust Inhibitors and substrates of thrombin
JP2703408B2 (ja) 1990-12-28 1998-01-26 麒麟麦酒株式会社 １，４‐ベンゾチアゼピン誘導体
WO1992011850A2 (en) * 1990-12-28 1992-07-23 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
CA2098702A1 (en) * 1990-12-28 1992-06-29 James C. Powers Peptide ketoamides, ketoacids, and ketoesters
WO1992019707A1 (en) * 1991-04-30 1992-11-12 The Procter & Gamble Company Liquid detergents with an aryl boronic acid
BR9205959A (pt) * 1991-04-30 1994-07-26 Procter & Gamble Detergentes líquidos reforçados com complexo bórico-poliol para inibir enzima proteolítica
EP0511456A1 (de) * 1991-04-30 1992-11-04 The Procter & Gamble Company Flüssiges Reinigungsmittel mit einem aromatischen Boratester zur Inhibierung des proteolytischen Enzyms
US5554728A (en) * 1991-07-23 1996-09-10 Nexstar Pharmaceuticals, Inc. Lipid conjugates of therapeutic peptides and protease inhibitors
EP0636143B1 (de) * 1992-04-16 1997-09-24 Zeneca Limited Peptide mit eine alphaaminoboronaire gruppe and ihre verwendung als elastasehemmer
WO1993021213A1 (en) * 1992-04-16 1993-10-28 Zeneca Limited Alpha-aminoboronic acid peptides and their use as elastase inhibitors
EP0583536B1 (de) 1992-08-14 1997-03-05 The Procter & Gamble Company Alpha-aminoborsäurehaltige flüssige Waschmittel
AU676721B2 (en) 1993-02-10 1997-03-20 Dana-Farber Cancer Institute Role of ATP-ubiquitin-dependent proteolysis in MHC-1 restricted antigen presentation and inhibitors thereof
US5384410A (en) * 1993-03-24 1995-01-24 The Du Pont Merck Pharmaceutical Company Removal of boronic acid protecting groups by transesterification
DE4311835A1 (de) * 1993-04-07 1994-10-13 Boehringer Ingelheim Int Verfahren zur Inhibierung der Transkription von Genen
US5424904A (en) 1993-10-04 1995-06-13 Taylor, Sr.; Thomas T. Circuit for electrically controlled intermittent motion
IL111176A0 (en) * 1993-10-07 1994-12-29 Du Pont Merck Pharma Dipeptide boronic acid inhibitors of trypsin-like enzymes and pharmaceutical compositions containing them
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6660268B1 (en) * 1994-03-18 2003-12-09 The President And Fellows Of Harvard College Proteasome regulation of NF-KB activity
US5574017A (en) 1994-07-05 1996-11-12 Gutheil; William G. Antibacterial agents
US6083903A (en) * 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US5614649A (en) * 1994-11-14 1997-03-25 Cephalon, Inc. Multicatalytic protease inhibitors
US5550262A (en) * 1994-11-14 1996-08-27 Cephalon, Inc. Multicatalytic protease inhibitors
DK1355910T3 (da) * 2001-01-25 2011-06-27 Us Of America Represented By The Secretary Dept Of Health And Human Services Formulering af borsyreforbindelser
DK2377869T3 (da) * 2004-03-30 2014-04-14 Millennium Pharm Inc Syntese af Bortezomib

Also Published As

Publication number Publication date
KR970706824A (ko) 1997-12-01
DK1312609T3 (da) 2006-05-15
ES2254803T3 (es) 2006-06-16
CA2203936C (en) 2005-04-12
NL300151I2 (nl) 2004-09-01
NO2004004I2 (no) 2007-09-10
FI114801B (fi) 2004-12-31
LU91083I2 (fr) 2004-08-09
DE69530936T2 (de) 2004-02-26
EP1312609B1 (de) 2005-12-28
ATE241631T1 (de) 2003-06-15
CA2203936A1 (en) 1996-05-09
IL133831A (en) 2004-03-28
EP1997823A1 (de) 2008-12-03
CN101077875A (zh) 2007-11-28
CN101077875B (zh) 2011-01-26
ES2199257T7 (es) 2010-03-31
US6066730A (en) 2000-05-23
US7531526B2 (en) 2009-05-12
FI971746A (fi) 1997-06-06
NO971929L (no) 1997-06-12
DE69530936D1 (de) 2003-07-03
ATE411324T1 (de) 2008-10-15
US20040167332A1 (en) 2004-08-26
US20020173488A1 (en) 2002-11-21
EP1627880B1 (de) 2008-10-15
ES2199257T3 (es) 2004-02-16
IL137726A (en) 2004-08-31
US20070282100A1 (en) 2007-12-06
EP0788360B1 (de) 2003-05-28
DK0788360T3 (da) 2003-09-22
CA2496538A1 (en) 1996-05-09
FI20041415A (fi) 2004-11-03
JP3717934B2 (ja) 2005-11-16
DE69534727T2 (de) 2006-09-14
ES2314540T3 (es) 2009-03-16
US6083903A (en) 2000-07-04
DE69535866D1 (de) 2008-11-27
ATE314378T1 (de) 2006-01-15
EP0788360B3 (de) 2009-08-12
NZ337211A (en) 2000-12-22
US20030199561A1 (en) 2003-10-23
DE122004000025I2 (de) 2006-09-07
AU4139896A (en) 1996-05-23
EP1312609A1 (de) 2003-05-21
HK1087714A1 (en) 2006-10-20
US20060122390A1 (en) 2006-06-08
US6747150B2 (en) 2004-06-08
WO1996013266A1 (en) 1996-05-09
US6465433B1 (en) 2002-10-15
US8378099B2 (en) 2013-02-19
DK1627880T3 (da) 2008-12-08
NO2004004I1 (no) 2004-08-06
FR04C0014I2 (de) 2005-05-21
JPH10510245A (ja) 1998-10-06
CN1168633A (zh) 1997-12-24
IL115790A (en) 2002-12-01
US20090247731A1 (en) 2009-10-01
DK0788360T5 (da) 2017-09-18
US6548668B2 (en) 2003-04-15
FI971746A0 (fi) 1997-04-23
NO310558B1 (no) 2001-07-23
PT788360E (pt) 2003-10-31
KR100398944B1 (ko) 2004-06-04
US20150072942A1 (en) 2015-03-12
CH0788360H1 (de) 2006-03-15
MX9703063A (es) 1998-07-31
TW318850B (de) 1997-11-01
CA2496538C (en) 2011-08-02
IL115790A0 (en) 1996-01-19
EP1627880A1 (de) 2006-02-22
EP0788360A4 (de) 1998-05-06
US20110306560A1 (en) 2011-12-15
PT1312609E (pt) 2006-05-31
US20130310320A1 (en) 2013-11-21
AU710564B2 (en) 1999-09-23
CY2484B1 (en) 2005-06-03
FR04C0014I1 (de) 2004-09-17
DE69530936C5 (de) 2007-02-22
NO971929D0 (no) 1997-04-25
DE69530936T3 (de) 2010-08-26
HK1002059A1 (en) 1998-07-31
IL133831A0 (en) 2001-04-30
US6297217B1 (en) 2001-10-02
FI120974B (fi) 2010-05-31
US8003791B2 (en) 2011-08-23
PT1627880E (pt) 2009-01-23
US7119080B2 (en) 2006-10-10
NL300151I1 (nl) 2004-08-02
US5780454A (en) 1998-07-14
EP0788360A1 (de) 1997-08-13
AU710564C (en) 1996-05-23
NZ296717A (en) 1999-11-29
US6617317B1 (en) 2003-09-09
IL137726A0 (en) 2001-10-31
US20080132678A1 (en) 2008-06-05
DE69534727D1 (de) 2006-02-02
CN1305475C (zh) 2007-03-21
LU91083I9 (de) 2018-12-28

Similar Documents

Publication Publication Date Title
DE122004000025I1 (de) Borons{ure-und-Esterverbindungen, deren Systhese und Verwendungen.
BR9808491A (pt) Compostos calcilìticos
MA23778A1 (fr) Purine-6-ones-2,9 disubstituees
ITTO940231A0 (it) Luce dinamica per applicazioni cromoterapeutiche.
HU905062D0 (en) Process for producing new 2-(rs)-substituted 2,3-dihydro-5-oxy-4,6,7-trimethyl-benzofurane compounds
PT768304E (pt) N-(pirimidinil)-benzenossulfonamidas como medicamentos
TR199501553A2 (tr) Sefem bilesimleri ve bunlarin farmasötik olarak kullanilmasi.
ES2073495T3 (es) Benzotiazepinas.
TR199801087T2 (xx) 4,10 �- diasetoksi-2alfa-Benzoiloksi- 5 �, 20 epoksi-1- hidroksi-9- okso-19- norsiklopropa(G) taks-11- en- 13alfa-il
BR9501651A (pt) Mesa veterinária
ES1029889Y (es) Baliza aerostatica perfeccionada.
FI2295U1 (fi) Polttomoottorikäyttöinen virtalähde
ES1030048Y (es) Juego de mesas.
DE29520906U1 (de) Direkt aufgelagertes, begrünbares Gleissystem